About
Ophthalmic Medicines
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (4)
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
752
By Phase
PHASE2: 3PHASE1: 1
By Status
COMPLETED: 4TERMINATED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05063734Lead Sponsor
A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
PHASE2Terminated
16 participants
Started: Aug 27, 2021 · Completed: Jun 29, 2022
NCT04281186Collaborator
Retinal and Cognitive Dysfunction in Type 2 Diabetes
N/ACompleted
510 participants
Started: Nov 16, 2020 · Completed: Dec 31, 2024
NCT04527107Lead Sponsor
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
PHASE2Completed
135 participants
Started: Jul 31, 2020 · Completed: Nov 22, 2023
NCT03499223Lead Sponsor
A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
PHASE2Completed
70 participants
Started: Apr 20, 2018 · Completed: Jul 18, 2019
NCT00702494Collaborator
Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
PHASE1Completed
21 participants
Started: Jun 30, 2008 · Completed: Sep 30, 2009
Locations (1)
Headquarters
Leuven, Belgium
Map
Loading map...